Multiregion human bladder cancer sequencing reveals tumour evolution, bladder cancer phenotypes and implications for targeted therapy

被引:27
|
作者
Heide, Timon [1 ]
Maurer, Angela [1 ]
Eipel, Monika [1 ]
Knoll, Katrin [1 ]
Geelvink, Mirja [1 ]
Veeck, Juergen [1 ]
Knuechel, Ruth [1 ]
van Essen, Julius [2 ]
Stoehr, Robert [3 ]
Hartmann, Arndt [3 ]
Altmueller, Janine [4 ,5 ]
Graham, Trevor A. [6 ]
Gaisa, Nadine T. [1 ]
机构
[1] Rhein Westfal TH Aachen, Inst Pathol, Pauweisstr 30, D-52074 Aachen, Germany
[2] Rhein Westfal TH Aachen, Univ Hosp, Dept Urol, Aachen, Germany
[3] Univ Erlangen Nuernberg, Inst Pathol, Erlangen, Germany
[4] Univ Cologne, CCG, Cologne, Germany
[5] Univ Cologne, Ctr Mol Med Cologne, Cologne, Germany
[6] Queen Mary Univ London, Barts & London Sch Med & Dent, Bans Canc Inst, London, England
来源
JOURNAL OF PATHOLOGY | 2019年 / 248卷 / 02期
基金
英国工程与自然科学研究理事会;
关键词
bladder cancer; phylogenetic analysis; tumour heterogeneity; tumour evolution; tumour phenotype; kataegis; TRANSITIONAL-CELL CARCINOMA; CLONAL EVOLUTION; FGFR3; MUTATIONS; COPY NUMBER; FRAMEWORK; INSIGHTS;
D O I
10.1002/path.5250
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We present an evolutionary analysis of the relative time of genetic events underlying tumorigenesis in human bladder cancers from 10 whole cystectomy specimens using multiregional whole-exome sequencing. We timed bladder cancer drivers, mutational signatures, ploidy and copy number alterations, provided evidence for kataegis and correlated alterations with tumour areas and histological phenotypes. We found that: (1) heterogeneous tumour areas/phenotypes had distinct driver mutations, (2) papillary-invasive tumours divided early into two parallel evolving branches and (3) parallel evolution of subclonal driver mutations occurred. APOBEC mutational signatures were found to be very early events, active in carcinoma in situ, and often remained a dominant source of mutations throughout tumour evolution. Genetic progression from carcinoma in situ followed driver mutations in NA13/FAT1, ZBTB7B or EP300/USP28/KMT2D. Our results point towards a more diverse mutational trajectory of bladder tumorigenesis and underpin the importance of timing of mutational processes and clonal architecture in bladder cancer as important aspects for successful prognostication and therapy. Copyright (c) 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:230 / 242
页数:13
相关论文
共 50 条
  • [1] Targeted therapy for metastatic bladder cancer
    vom Dorp, F.
    Boergermann, C.
    Rose, A.
    Becker, M.
    Ruebben, H.
    UROLOGE, 2008, 47 (10): : 1311 - +
  • [2] Emerging Targeted Therapy for Bladder Cancer
    Thibault, Constance
    Loriot, Yohann
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (03) : 585 - 596
  • [3] The evolution of intravesical therapy for bladder cancer
    Pham, Cecile
    Cohen, Jordan
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 : 83 - 83
  • [4] Identification of genes associated with gall bladder cell carcinogenesis: Implications in targeted therapy of gall bladder cancer
    Ghosh, Ishita
    Dey Ghosh, Ruma
    Mukhopadhyay, Soma
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (12)
  • [5] Chemotherapy and Targeted Therapy for Gall Bladder Cancer
    Sirohi B.
    Singh A.
    Jagannath P.
    Shrikhande S.V.
    Indian Journal of Surgical Oncology, 2014, 5 (2) : 134 - 141
  • [6] Emerging drugs for targeted therapy of bladder cancer
    Agarwal, Piyush K.
    Black, Peter C.
    McConkey, David J.
    Dinney, Colin P. N.
    EXPERT OPINION ON EMERGING DRUGS, 2007, 12 (03) : 435 - 448
  • [7] Enhancing mTOR targeted therapy in bladder cancer
    Becker, Marie N.
    Copland, John A.
    Williams, Christopher R.
    CANCER RESEARCH, 2012, 72
  • [8] Functional Nanomedicines for Targeted Therapy of Bladder Cancer
    Tang, Chao
    Liu, Heng
    Fan, Yanpeng
    He, Jiahao
    Li, Fuqiu
    Wang, Jin
    Hou, Yuchuan
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [9] Erdafitinib: The first targeted therapy for bladder cancer
    Darling, H. S.
    INDIAN JOURNAL OF CANCER, 2019, 56 (03) : 287 - 288
  • [10] Clinical applications for targeted therapy in bladder cancer
    Adam, L
    Kassouf, W
    Dinney, CPN
    UROLOGIC CLINICS OF NORTH AMERICA, 2005, 32 (02) : 239 - +